Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.5K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.5K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.2K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

562
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
562
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

581
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
581
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

371
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
371
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

40
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
40

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Brain-Penetrant Nurr1 Agonist Tool.

ChemMedChem·2026
Same author

First Structure-Activity-Relationship Study of Potent G2A Antagonists.

Journal of medicinal chemistry·2026
Same author

Silymarin and Its Isolated Flavanonol Lignans Are Liver X Receptor Antagonists.

Archiv der Pharmazie·2026
Same author

An Activator of Tailless' Repressor Function Stimulates Anti-Neurodegenerative Gene Expression.

Journal of medicinal chemistry·2026
Same author

Enhanced Intramuscular mRNA Activity of Peptide-Lipid Nanoparticles with Hydrophobized Head Groups.

Bioconjugate chemistry·2026
Same author

An Agonist/Antagonist Photo-Switchable Vitamin D Mimetic Enables Bidirectional Optical Control of VDR.

Angewandte Chemie (International ed. in English)·2026

Related Experiment Video

Updated: Nov 1, 2025

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

3.1K

Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics.

Moritz Helmstädter1, Astrid Kaiser1, Steffen Brunst1

  • 1Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

Journal of Medicinal Chemistry
|June 24, 2021
PubMed
Summary
This summary is machine-generated.

Developing novel dual farnesoid X receptor activators/soluble epoxide hydrolase inhibitors (FXRa/sEHi) offers a promising therapeutic strategy for non-alcoholic steatohepatitis (NASH). Compound 13 demonstrates improved pharmacokinetics for preclinical development.

More Related Videos

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.7K
Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor
09:21

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Published on: January 4, 2016

10.1K

Related Experiment Videos

Last Updated: Nov 1, 2025

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine
08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

3.1K
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.7K
Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor
09:21

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Published on: January 4, 2016

10.1K

Area of Science:

  • Hepatology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Non-alcoholic steatohepatitis (NASH) is a prevalent chronic liver disease linked to metabolic disorders, characterized by fat accumulation, inflammation, and fibrosis.
  • Current pharmacological treatments for NASH are limited despite its global epidemic scale.
  • Combined therapeutic approaches targeting multiple NASH factors are hypothesized to enhance efficacy.

Purpose of the Study:

  • To develop improved dual FXRa/sEHi with enhanced pharmacokinetic properties for NASH treatment.
  • To address the limitations of first-generation FXRa/sEHi, including poor metabolic stability and short in vivo half-life.
  • To identify optimized compounds for preclinical development.

Main Methods:

  • Systematic structure-activity and structure-stability relationship studies of FXRa/sEHi chemotypes.
  • Development and characterization of second-generation FXRa/sEHi.
  • Evaluation of pharmacokinetic parameters, including plasma exposure and half-life.
  • Assessment of dual potency on FXR and sEH targets.

Main Results:

  • Second-generation FXRa/sEHi were synthesized with improved pharmacokinetic profiles.
  • Compound 13 exhibited a half-life exceeding 5 hours and high plasma exposure.
  • Compound 13 maintained dual potency comparable to first-generation compounds.
  • The optimized FXRa/sEHi demonstrated significant potential for preclinical development.

Conclusions:

  • Optimized dual FXRa/sEHi represent a promising therapeutic avenue for NASH.
  • Compound 13 shows substantial preclinical potential due to its improved pharmacokinetic characteristics.
  • Further development of compound 13 could lead to effective pharmacological interventions for NASH.